Cheminformatics techniques in antimalarial drug discovery and development from natural products 1: basic concepts

References

[1] Price M History of ancient medicine in Mesopotamia and Iran. Iranchamber.com, October 2001.Search in Google Scholar

[2] Willcox M, Bodeker G, Rasoanaivo P, Addae-Kyereme J. Traditional medicinal plants and malaria. Boca Raton, Florida 33431: CRC Press, 2004: ISBN 9780415301121.10.1201/9780203502327Search in Google Scholar

[3] Yuan H, Ma Q, Ye L, Piao G. The traditional medicine and modern medicine from natural products. Molecules. 2016;21:559.10.3390/molecules21050559Search in Google Scholar

[4] O’Neill PM, Ward SA, Berry NG, Jeyadevan J, Biagini GA, Asadollaly E, et al. A medicinal chemistry perspective on 4-aminoquinoline antimalarial drugs. Curr Top Med Chem. 2006;6:479–507.10.2174/156802606776743147Search in Google Scholar PubMed

[5] ElSohly HN, Croom EM, Jr, El-Feraly FS, El-Sherei MM. A large-scale extraction technique of artemisinin from Artemisia annua. J Nat Prod. 1990;53:1560–4.10.1021/np50072a026Search in Google Scholar

[6] De Vries PJ, Dien TK. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs. 1996;52:818–36.10.2165/00003495-199652060-00004Search in Google Scholar PubMed

[7] Price RN, Nosten F, Luxemburger C, Ter Kuile F, Paiphun L, Chongsuphajaisiddhi T, et al. Effects of artemisinin derivatives on malaria transmissibility. The Lancet. 1996;347:1654–8.10.1016/S0140-6736(96)91488-9Search in Google Scholar

[8] World Health Organization. Guidelines for the treatment of malaria. CH-1211 Geneva 27 Switzerland: World Health Organization, 2006.Search in Google Scholar

[9] World Health Organization. Guidelines for the treatment of malaria. CH-1211 Geneva 27 Switzerland: World Health Organization, 2015.Search in Google Scholar

[10] Laurent D, Pietra F. Antiplasmodial marine natural products in the perspective of current chemotherapy and prevention of malaria. A review. Mar Biotechnol. 2006;8:433–47.10.1007/s10126-006-6100-ySearch in Google Scholar PubMed

[11] Kaur K, Jain M, Kaur T, Jain R. Antimalarials from nature. Bioorg Med Chem. 2009;17:3229–56.10.1016/j.bmc.2009.02.050Search in Google Scholar PubMed

[12] Batista R, De Jesus Silva Júnior A, De Oliveira AB. Plant-derived antimalarial agents: new leads and efficient phytomedicines. Part II. Non-alkaloidal natural products. Molecules. 2009;14:3037–72.10.3390/molecules14083037Search in Google Scholar PubMed PubMed Central

[13] Mojab F. Antimalarial natural products: a review. Avicenna J Phytomedicine. 2012;2:52.Search in Google Scholar

[14] Nondo RS, Zofou D, Moshi MJ, Erasto P, Wanji S, Ngemenya MN, et al. Ethnobotanical survey and in vitro antiplasmodial activity of medicinal plants used to treat malaria in Kagera and Lindi regions, Tanzania. J Med Plants Res. 2015;9:179–92.10.5897/JMPR2014.5685Search in Google Scholar

[15] Harvey AL, Edrada-Ebel R, Quinn RJ. The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discovery. 2015;14:111.10.1038/nrd4510Search in Google Scholar

[16] Jamal S, Grover A. Cheminformatics approaches in modern drug discovery. InDrug Design: principles and Applications. Singapore: Springer, 2017:135–48.10.1007/978-981-10-5187-6_9Search in Google Scholar

[17] Gasteiger J. Handbook of chemoinformatics. Weinheim, Germany: Wiley-VCH, 2003:3–5.10.1002/9783527618279.ch1Search in Google Scholar

[18] Ertl P. Cheminformatics and its role in the modern drug discovery process. Basel, Switzerland: University of Strasbourg. Novartis. nd Web 2014:18.Search in Google Scholar

[19] Weisgerber DW. Chemical abstracts service chemical registry system: history, scope, and impacts. J Am Soc Inf Sci. 1997;48:349–60.10.1002/(SICI)1097-4571(199704)48:4<349::AID-ASI8>3.0.CO;2-WSearch in Google Scholar

[20] Covell DG. In: Tudor Oprea (University of New Mexico), editor. Chemoinformatics in drug discovery. Weinheim: Wiley-VCH, 2005:xxii 493. 17 × 25 cm. ISBN 3-527-30753-2.Search in Google Scholar

[21] Brown FK. Chemoinformatics: what is it and how does it impact drug discovery. Annu Rep Med Chem. 1998;33:375–84.10.1016/S0065-7743(08)61100-8Search in Google Scholar

[22] Ekins S, Freundlich JS, Hobrath JV, White EL, Reynolds RC. Combining computational methods for hit to lead optimization in Mycobacterium tuberculosis drug discovery. Pharm Res. 2014;31:414–35.10.1007/s11095-013-1172-7Search in Google Scholar PubMed

[23] Tian S, Wang J, Li Y, Li D, Xu L, Hou T. The application of in silico drug-likeness predictions in pharmaceutical research. Adv Drug Deliv Rev. 2015;23:2–10.10.1016/j.addr.2015.01.009Search in Google Scholar

[24] Hu Y, Stumpfe D, Bajorath J. Lessons learned from molecular scaffold analysis. J Chem Inf Model. 2011;51:1742–53.10.1021/ci200179ySearch in Google Scholar PubMed

[25] Yongye AB, Waddell J, Medina‐Franco JL. Molecular scaffold analysis of natural products databases in the public domain. Chem Biol Drug Des. 2012;80:717–24.10.1111/cbdd.12011Search in Google Scholar PubMed

[26] Topliss J. Quantitative structure-activity relationships of drugs. Amsterdam, Netherlands: Elsevier, 2012.Search in Google Scholar

[27] Reymond J, Ruddigkeit L, Blum L, van Deursen R. The enumeration of chemical space. Wiley Interdiscip Rev: Comput Mol Sci. 2012;2:717–33.10.1002/wcms.1104Search in Google Scholar

[28] Sud M, Fahy E, Subramaniam S. Template-based combinatorial enumeration of virtual compound libraries for lipids. J Cheminform. 2012;4:23.10.1186/1758-2946-4-23Search in Google Scholar PubMed PubMed Central

[29] Sanhueza CA, Cartmell J, El-Hawiet A, Szpacenko A, Kitova EN, Daneshfar R, et al. Evaluation of a focused virtual library of heterobifunctional ligands for Clostridium difficile toxins. Org Biomol Chem. 2015;13:283–98.10.1039/C4OB01838ASearch in Google Scholar PubMed

[30] Feunang YD, Eisner R, Knox C, Chepelev L, Hastings J, Owen G, et al. ClassyFire: automated chemical classification with a comprehensive, computable taxonomy. J Cheminform. 2016;8:61.10.1186/s13321-016-0174-ySearch in Google Scholar PubMed PubMed Central

[31] Ghahremanpour MM, Van Maaren PJ, Van Der Spoel D. The Alexandria library, a quantum-chemical database of molecular properties for force field development. Sci Data. 2018;5:180062.10.1038/sdata.2018.62Search in Google Scholar PubMed PubMed Central

[32] Todeschini R, Consonni V. Handbook of molecular descriptors. Weinheim: John Wiley & Sons, 2008.Search in Google Scholar

[33] Planey SL, Kumar R. Lipophilicity indices for drug development. J Appl Biopharm Pharmacokinet. 2013;1:31–6.10.14205/2309-4435.2013.01.01.6Search in Google Scholar

[34] Kratochvíl M, Vondrášek J, Galgonek J. Sachem: a chemical cartridge for high-performance substructure search. J Cheminform. 2018;10:27.10.1186/s13321-018-0282-ySearch in Google Scholar PubMed PubMed Central

[35] Evans DA. History of the Harvard ChemDraw project. Angew Chem Int Ed. 2014;53:11140–5.10.1002/anie.201405820Search in Google Scholar PubMed

[36] Backman TW, Cao Y, Girke T. ChemMine tools: an online service for analyzing and clustering small molecules. Nucleic Acids Res. 2011;39:W486–91.10.1093/nar/gkr320Search in Google Scholar PubMed PubMed Central

[37] Skinnider MA, Dejong CA, Franczak BC, McNicholas PD, Magarvey NA. Comparative analysis of chemical similarity methods for modular natural products with a hypothetical structure enumeration algorithm. J Cheminform. 2017;9:46.10.1186/s13321-017-0234-ySearch in Google Scholar PubMed PubMed Central

[38] Saldívar-González FI, Naveja JJ, Palomino-Hernández O, Medina-Franco JL. Getting SMARt in drug discovery: chemoinformatics approaches for mining structure–multiple activity relationships. RSC Adv. 2017;7:632–41.10.1039/C6RA26230ASearch in Google Scholar

[39] Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717.10.1038/srep42717Search in Google Scholar PubMed PubMed Central

[40] Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discov Today. 2018;23:1241–50.10.1016/j.drudis.2018.01.039Search in Google Scholar PubMed

[41] Hessler G, Baringhaus K. Artificial intelligence in drug design. Molecules. 2018;23:2520.10.3390/molecules23102520Search in Google Scholar PubMed PubMed Central

[42] Ekins S, Clark AM, Dole K, Gregory K, Mcnutt AM, Spektor AC. Data mining and computational modeling of high-throughput screening datasets. Methods in Molecular Biology. Heidelberg: Springer, 2018:197–221.10.1007/978-1-4939-7724-6_14Search in Google Scholar PubMed PubMed Central

[43] Grisoni F, Ballabio D, Todeschini R, Consonni V. Molecular descriptors for structure–activity applications: a hands-on approach. Computational toxicology. Heidelberg: Springer, 2018:3–53.10.1007/978-1-4939-7899-1_1Search in Google Scholar PubMed

[44] Subramanian U, Sivapunniyam A, Pudukadu Munusamy A, Sundaram R. An in silico approach towards the prediction of druglikeness properties of inhibitors of plasminogen activator inhibitor1. Adv Bioinf. 2014;2014:385418.10.1155/2014/385418Search in Google Scholar PubMed PubMed Central

[45] Tian S, Wang J, Li Y, Li D, Xu L, Hou T. The application of in silico drug-likeness predictions in pharmaceutical research. Adv Drug Deliv Rev. 2015;86:2–10.10.1016/j.addr.2015.01.009Search in Google Scholar PubMed

[46] Wu Y, Hu M, Yang L, Li X, Bian J, Jiang F, et al. Novel natural-product-like caged xanthones with improved druglike properties and in vivo antitumor potency. Bioorg Med Chem Lett. 2015;15:2584–8.10.1016/j.bmcl.2015.04.031Search in Google Scholar PubMed

[47] Wawer MJ, Li K, Gustafsdottir SM, Ljosa V, Bodycombe NE, Marton MA, et al. Toward performance-diverse small-molecule libraries for cell-based phenotypic screening using multiplexed high-dimensional profiling. Proceedings of the National Academy of Sciences. 2014;111:10911–16.10.1073/pnas.1410933111Search in Google Scholar PubMed PubMed Central

[48] Giroud C, Du Y, Marin M, Min Q, Jui NT, Fu H, et al. Screening and functional profiling of small-molecule HIV-1 entry and fusion inhibitors. Assay Drug Dev Technol. 2017;15:53–63.10.1089/adt.2017.777Search in Google Scholar PubMed PubMed Central

[49] Xia J, Hu H, Xue W, Wang XS, Wu S. The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay. J Enzyme Inhib Med Chem. 2018;33:525–35.10.1080/14756366.2018.1437156Search in Google Scholar PubMed

[50] Scott JS, Waring MJ. Practical application of ligand efficiency metrics in lead optimisation. Bioorg Med Chem. 2018;26:3006–15.10.1016/j.bmc.2018.04.004Search in Google Scholar PubMed

[51] Heikal A, Nakatani Y, Jiao W, Wilson C, Rennison D, Weimar MR, et al. ‘Tethering’fragment-based drug discovery to identify inhibitors of the essential respiratory membrane protein type II NADH dehydrogenase. Bioorg Med Chem Lett. 2018;28:2239–43.10.1016/j.bmcl.2018.05.048Search in Google Scholar PubMed

[52] Stamford AW, Scott JD, Li SW, Babu S, Tadesse D, Hunter R, et al. Discovery of an orally available, brain penetrant BACE1 inhibitor that affords robust CNS Aβ reduction. ACS Med Chem Lett. 2012;3:897–902.10.1021/ml3001165Search in Google Scholar PubMed

[53] Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discov Today. 2004;9:430–1.10.1016/S1359-6446(04)03069-7Search in Google Scholar PubMed

[54] Carr RA, Congreve M, Murray CW, Rees DC. Fragment-based lead discovery: leads by design. Drug Discov Today. 2005;10:987–92.10.1016/S1359-6446(05)03511-7Search in Google Scholar PubMed

[55] Mortenson PN, Murray CW. Assessing the lipophilicity of fragments and early hits. J Comput Aided Mol Des. 2011;25:663–7.10.1007/s10822-011-9435-zSearch in Google Scholar PubMed

[56] Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discovery. 2007;6:881–90.10.1038/nrd2445Search in Google Scholar PubMed

[57] Mowbray CE, Burt C, Corbau R, Gayton S, Hawes M, Perros M, et al. Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate. Bioorg Med Chem Lett. 2009;19:5857–60.10.1016/j.bmcl.2009.08.080Search in Google Scholar PubMed

[58] Tarcsay A, Nyíri K, Keserű GM. Impact of lipophilic efficiency on compound quality. J Med Chem. 2012;55:1252–60.10.1021/jm201388pSearch in Google Scholar PubMed

[59] Wager TT, Chandrasekaran RY, Hou X, Troutman MD, Verhoest PR, Villalobos A, et al. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chem Neurosci. 2010;1:420–34.10.1021/cn100007xSearch in Google Scholar PubMed

[60] Keserü GM, Makara GM. The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discovery. 2009;8:203–12.10.1038/nrd2796Search in Google Scholar

[61] Egieyeh SA, Syce J, Malan SF, Christoffels A. Prioritization of anti-malarial hits from nature: chemo-informatic profiling of natural products with in vitro antiplasmodial activities and currently registered anti-malarial drugs. Malar J. 2016;15:50.10.1186/s12936-016-1087-ySearch in Google Scholar PubMed

[62] Larose DT. Discovering knowledge in data: an introduction to data mining. Hoboken, New Jersey.: John Wiley & Sons, 2014.Search in Google Scholar

[63] Thomas MC, Zhu W, Romagnoli JA. Data mining and clustering in chemical process databases for monitoring and knowledge discovery. J Process Control. 2018;67:160–75.10.1016/j.jprocont.2017.02.006Search in Google Scholar

[64] In: Bajorath J, Bajorath J, editor(s). Chemoinformatics and computational chemical biology. Totowa, New Jersey: Humana Press, 2011.10.1007/978-1-60761-839-3Search in Google Scholar

[65] Bajorath J. Chemoinformatics: concepts, methods, and tools for drug discovery. Heidelberg: Springer Science & Business Media, 2004.10.1385/1592598021Search in Google Scholar

[66] Sheridan RP, Kearsley SK. Why do we need so many chemical similarity search methods? Drug Discov Today. 2002;7:903–11.10.1016/S1359-6446(02)02411-XSearch in Google Scholar PubMed

[67] Varnek A, Tropsha A. Chemoinformatics approaches to virtual screening. Cambridge, United Kingdom: Royal Society of Chemistry, 2008.10.1039/9781847558879Search in Google Scholar

[68] Guha R. Exploring structure–activity data using the landscape paradigm. Wiley Interdiscip Rev: Comput Mol Sci. 2012;2:829–41.10.1002/wcms.1087Search in Google Scholar PubMed PubMed Central

[69] Hu Y, Stumpfe D, Bajorath J. Advancing the activity cliff concept. F1000Research. 2013;2:199.10.12688/f1000research.2-199.v1Search in Google Scholar PubMed PubMed Central

[70] Stumpfe D, Hu Y, Dimova D, Bajorath J. Recent progress in understanding activity cliffs and their utility in medicinal chemistry: miniperspective. J Med ChemJJ. 2013;57:18–28. DOI: 10.1021/jm401120g.Search in Google Scholar PubMed

[71] Maggiora GM. On outliers and activity cliffs why QSAR often disappoints. J Chem Inf Model. 2006;46:1535–1535.10.1021/ci060117sSearch in Google Scholar PubMed

[72] Sander T, Freyss J, von Korff M, Rufener C. DataWarrior: an open-source program for chemistry aware data visualization and analysis. J Chem Inf Model. 2015;55:460–73.10.1021/ci500588jSearch in Google Scholar PubMed

[73] Golbraikh A, Tropsha A. 12 QSAR/QSPR revisited. In: Engel T, Gasteiger J, editor(s). Chemoinformatics: basic concepts and methods. Weinheim: Wiley-VCH, 2018:465.10.1002/9783527816880.ch12Search in Google Scholar

[74] Dimova D, Stumpfe D, Bajorath J. Systematic assessment of coordinated activity cliffs formed by kinase inhibitors and detailed characterization of activity cliff clusters and associated SAR information. Eur J Med Chem. 2015;90:414–27.10.1016/j.ejmech.2014.11.058Search in Google Scholar PubMed

[75] Naveja JJ, Medina-Franco JL. Activity landscape of DNA methyltransferase inhibitors bridges chemoinformatics with epigenetic drug discovery. Expert Opin Drug Discov. 2015;10:1059–70.10.1517/17460441.2015.1073257Search in Google Scholar PubMed

[76] Ojeda-Montes MJ, Gimeno A, Tomas‐Hernández S, Cereto‐Massagué A, Beltrán‐Debón R, Valls C, et al. Activity and selectivity cliffs for DPP-IV inhibitors: lessons we can learn from SAR studies and their application to virtual screening. Med Res Rev. 2018;38:1874–915.10.1002/med.21499Search in Google Scholar PubMed

[77] Afendi FM, Ono N, Nakamura Y, Nakamura K, Darusman LK, Kibinge N, et al. Data mining methods for omics and knowledge of crude medicinal plants toward big data biology. Comput Struct Biotechnol J. 2013;4:1–14.10.5936/csbj.201301010Search in Google Scholar PubMed PubMed Central

[78] Baumann K, Becker GF, Mestres J, Schneider G. Systems approaches and big data in molecular informatics. Mol Inform. 2015;34:2–2.10.1002/minf.201580131Search in Google Scholar PubMed

[79] Fourches D. Cheminformatics: at the crossroad of eras. Application of computational techniques in pharmacy and medicine. Heidelberg: Springer, 2014:539–46.10.1007/978-94-017-9257-8_16Search in Google Scholar

[80] Melagraki G, Afantitis A. Editorial [Thematic issue: advances in cheminformatics: drug discovery, computational toxicology and nanomaterials [Part I]]. Comb Chem High Throughput Screen. 2015;18:236–7.10.2174/138620731803150423131038Search in Google Scholar PubMed

[81] Xu J, Hagler A. Chemoinformatics and drug discovery. Molecules. 2002;7:566–600.10.3390/70800566Search in Google Scholar